Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents (Q39568183)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 28, 2011

Language	Label	Description	Also known as
English	Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents	scientific article published on March 28, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents (English)

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

author name string

Preeti Raval

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Mukul Jain

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Amitgiri Goswami

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sujay Basu

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Archana Gite

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Atul Godha

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Harikishore Pingali

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Saurin Raval

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Suresh Giri

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Dinesh Suthar

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Maanan Shah

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Pankaj Patel

12

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

28 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0960894X11003398?httpAccept=text/xml

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

https://api.elsevier.com/content/article/PII:S0960894X11003398?httpAccept=text/plain

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Bioorganic & Medicinal Chemistry Letters

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

3103-3109

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PPAR ligands: potential therapies for metabolic syndrome

1

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Clinical interest of PPARs ligands

2

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Recent advances in peroxisome proliferator-activated receptor science

3

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

The PPARs: from orphan receptors to drug discovery

4

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?

5

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future

6

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

7

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

8

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Molecular Pharmacology

10

46

1070

author name string

Ibrahimi

publication date

1994

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

The pathogenesis of atherosclerosis--an update

11

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

12

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

13

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats

15

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

16

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation

17

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.

18

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

19

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes

20

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

PPAR dual agonists: are they opening Pandora's Box?

21

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress

22

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone

23

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

24

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

25

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar

26

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco

27

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

28

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists

31

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists

32

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Peroxisome Proliferator Activated Receptor-α Expression in Human Liver

33

1 reference

10.1016/J.BMCL.2011.03.020

https://api.crossref.org/works/10.1016/J.BMCL.2011.03.020

28 November 2024

Identifiers

10.1016/J.BMCL.2011.03.020

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39568183&oldid=2280868973"